Anti-PD-1 antibody

Anti-PD-1 antibody

What is an anti-PD-1 antibody?Antibody drug targeting the immune checkpoint molecule PD-1 expressed on activated T cellsIt inhibits the binding of PD-1 and its ligand PD-L1, thereby restoring the function of T cells that were suppressed by cancer cells and promoting anti-tumor immunity. It is widely used as a representative drug class in cancer immunotherapy and is primarily used for the treatment of various cancers such as lung cancer, malignant melanoma, and renal cell carcinoma.

Representative examples of anti-PD-1 antibodies

Nivolumab (Opdivo)

Nivolumab (Opdivo) is aThe first PD-1 inhibitory antibody approved in the worldIt inhibits the interaction with PD-L1 by binding to PD-1, thereby activating T cell anti-tumor immunity. As a representative drug of cancer immunotherapy, it is a prime example that has driven the widespread adoption and development of immune checkpoint inhibitors.

Pembrolizumab (Keytruda)

Pembrolizumab (Keytruda) isPD-1 inhibitory antibody that restores T cell anti-tumor immunity by inhibiting PD-1It is a representative immune checkpoint inhibitor used for a wide range of cancers, including lung cancer and malignant melanoma, and its efficacy and therapeutic effects may be evaluated with reference to biomarkers such as PD-L1 expression.

Cimiprimum (Ribtaver)

Semiprimab (Libtayo) is,PD-1 inhibitory antibody that activates T cell anti-tumor immunity by inhibiting PD-1It is a representative immune checkpoint inhibitor for which indications are expanding across multiple cancer types, including skin cancer. Anti-PD-1 antibodies are attracting attention as an area of drug discovery where indications are actively expanding and combination therapies are being developed.

Key challenges in anti-PD-1 antibody development

Management of patients who do not achieve an immune response

Anti-PD-1 antibodiesNot all patients achieve sufficient therapeutic effect.A challenge is primary resistance, where treatment is ineffective from the start, and acquired resistance, where its effectiveness is lost after treatment. As the tumor immune microenvironment significantly impacts drug efficacy, the development of new evaluation models that can reflect these factors is highly prioritized.

Response to tumor immune microenvironments varying by patient

With anti-PD-1 antibodies,PD-L1 expression alone is not sufficient to predict drug efficacyTherefore, biomarker exploration is being advanced, including TMB, MSI-H, and tumor-infiltrating lymphocytes (TILs). The utilization of patient-derived models, which can reflect the tumor immune microenvironment of individual patients, is also becoming important in drug efficacy prediction and drug discovery research.

How to predict immune-related adverse events (irAEs)

With anti-PD-1 antibodies,Autoimmune-like adverse events (irAEs) associated with immune activationis an important issue. Representative adverse events include pneumonia, colitis, liver injury, and endocrine disorders. In order to prevent severe cases, it is important to establish models that can evaluate safety not only clinically but also from the preclinical stage.

Non-clinical evaluation required for anti-PD-1 antibody development

Construct a pathological model that can replicate the tumor immune microenvironment.

In the evaluation of anti-PD-1 antibodies,Standard cell lines cannot fully replicate the tumor microenvironment (TME).Therefore, it is important to construct pathological models that combine syngeneic models, humanized mice, organoids, and other approaches to evaluate immune responses and the TME in a multifaceted manner.

Multifaceted evaluation of immunomodulatory activity and drug efficacy

In the evaluation of anti-PD-1 antibodies,A single evaluation method cannot fully capture immune activity or drug efficacy.It is important to evaluate from multiple perspectives by combining cancer immune assays, target engagement, flow cytometry, cytokine measurements, digital pathology, and biomarker analysis.

Integrate and evaluate pharmacokinetics and tissue distribution

With anti-PD-1 antibodies,Integrate and evaluate pharmacokinetics (PK) and intratumoral antibody kineticsis important. In addition to PK evaluation, it is possible to understand the relationship with drug efficacy by analyzing intratumoral distribution and tissue infiltration, and an evaluation strategy that combines PK and drug efficacy is increasingly required.

Evaluate immunotoxicity early on

With anti-PD-1 antibodies,To evaluate immunotoxicity multi-faceted from preclinical stages.is important. By combining the production of ADAs (anti-drug antibodies), prediction of cytokine storms, assessment of irAE risk, and long-term safety evaluation, clinical safety risks can be better predicted.

Key points when choosing a contract research organization (CRO) for non-clinical studies

In the development of anti-PD-1 antibodies, a non-clinical testing system capable of comprehensively evaluating efficacy, safety, and immune response is crucial. While indications will expand, combination therapies will progress, and biomarker development will advance, resistance and irAEs will pose challenges. The selection of a strategic CRO equipped with pathological models and evaluation systems that can address these issues will be the key to development success.